GlassScriptPhysician profile
Kimpreet K Aulakh
NPI 1104121524
$9,895.44
in general payments reported to CMS, 2019-2025
62 companies · $1,439 in 2025
The $1,439 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,900 · 2020: $677 · 2021: $1,682 · 2022: $1,685 · 2023: $910 · 2024: $1,604 · 2025: $1,439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,952.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,951.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,617.97 | 2019-2025 | Evenity, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $867.40 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $524.93 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Janssen Pharmaceuticals, INC | $479.45 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $441.69 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Astellas Pharma US INC | $428.75 | 2019-2025 | Veozah |
| Pfizer INC. | $385.36 | 2019-2025 | |
| Lilly USA, LLC | $374.00 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $372.32 | 2019-2025 | Shingrix, Arexvy |
| Esperion Therapeutics, INC. | $355.37 | 2020-2025 | Nexletol, Nexlizet |
| Novo Nordisk INC | $323.94 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $180.01 | 2019-2025 | |
| Amarin Pharma, INC. | $140.69 | 2019-2021 | |
| Abbott Laboratories | $131.01 | 2019-2022 | |
| Dynavax Technologies Corporation | $129.94 | 2022-2025 | Heplisav-B |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimpreet Aulakh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.